A Dopamine Agonist and a Gambling Problem: Continue, Taper, or Switch
A medication started specifically to delay dyskinesia has produced a different, unanticipated harm, and stopping it is not as simple as it sounds.
The joint bank statement was how the family found out, two weeks ago: roughly $40,000 moved out over four months to two online sports-betting platforms, none of it discussed beforehand. David M., 58, has spent three decades as a structural engineer, a career built on the kind of long-view caution his wife could not reconcile with what she was reading. He was diagnosed with Parkinson’s disease four years ago, at 54, younger than typical onset, and started on ropinirole rather than levodopa specifically because of his age — an agonist-first strategy meant to delay the dyskinesia that follows years of levodopa exposure, with levodopa to be added once agonist monotherapy stopped covering him. His tremor and bradykinesia have been reasonably controlled since on ropinirole alone, titrated up twice over the past two years. He has no personal or family history of gambling, problem drinking, or other impulsive behavior predating the medication. By his own account — given reluctantly, once his wife insisted he come in with her — he doesn’t understand why he keeps doing it even now that the damage is undeniable; he describes an urge disconnected from his usual judgment, not a decision he is making the way he makes any other decision.
That description — a compulsion experienced as alien to the patient’s own decision-making, arising only after a specific drug was started, with no prior vulnerability to suggest it was always going to surface — is the clinical signature dopamine agonists are known to produce in a meaningful minority of patients, through D3 receptor agonism concentrated in the mesolimbic reward pathway rather than the motor circuits the drug is prescribed to treat. It is not a rare idiosyncrasy: DOMINION, a cross-sectional survey of 3,090 PD patients, found an impulse control disorder in 17.1% of those on a dopamine agonist against 6.9% of those not — roughly one in six, and two to three times the odds. Notably, DOMINION did not find the agonist dose-response some smaller studies had reported; the dose relationship it did detect was with levodopa. Younger age was independently associated with an ICD in that analysis, alongside levodopa use, current smoking, and a family history of gambling problems — David was diagnosed at 54. What complicates the obvious fix, stopping the drug, is that agonists cannot always be withdrawn cleanly: a recognized withdrawal syndrome exists for this class, with anxiety, dysphoria, and cravings that don’t reliably resolve by substituting levodopa for the lost agonist effect. Nobody at the table yet knows whether David’s version of this compulsion will resolve smoothly once the drug is gone, or whether stopping it will trade one hard problem for another.
Clinic, brought in at his wife's insistence
This is a real, ongoing financial harm, still actively accumulating, and David himself describes an urge disconnected from his own judgment — that combination, arising only after starting ropinirole with no prior personal or family history, points squarely at the drug. I’d start the taper today. The longer he stays on it, the more this pattern is likely to continue doing real damage to his family.
I’m not disputing that this needs to stop — it does, and quickly. What I want on the record before we set a pace is that dopamine agonist withdrawal syndrome is real and doesn’t reliably resolve just by cross-titrating to levodopa. Rabinak and Nirenberg’s original case series first described it: severe anxiety, dysphoria, and drug cravings that persist even once adequate levodopa is in place.
Treating ‘stop the drug’ as if it’s automatically the safe move risks trading a harm we can see for one that’s harder to predict and, in some patients, doesn’t resolve on the timeline anyone would want.
Whatever pace the taper runs at, the medication change alone doesn’t undo four months of financial harm or guarantee it doesn’t recur, and David’s own insight into this is still partial. I’d start the cross-taper today, at whatever pace Neurology and Psychiatry settle on, and in parallel: his wife takes over their shared accounts as an immediate bridge measure, and a gambling-specific behavioral referral goes in today, not once the medication question is resolved.
Agreed: taper begins today with concurrent levodopa introduction. David's wife takes over the couple's shared financial accounts immediately as a bridge measure while the behavioral referral is arranged. Follow-up in one week rather than the usual interval, given the acuity.
Not agreed: how fast the taper should run. The Psychiatrist wanted a faster schedule given the ongoing harm; the Neurologist held firm on the slower pace given DAWS's own real severity, and neither treated the other's position as wrong — the actual week-to-week pace will be adjusted based on how David tolerates the first reduction. Also unresolved: whether his partial insight will improve enough, once the agonist is out of his system, to genuinely engage with the referral, or whether real harm has already reshaped his financial life regardless of what happens next with the drug.